DK1691805T3 - Anvendelse af urocansyre som er i stand til at omdanne celle cytoplasm til syre - Google Patents

Anvendelse af urocansyre som er i stand til at omdanne celle cytoplasm til syre

Info

Publication number
DK1691805T3
DK1691805T3 DK04798326T DK04798326T DK1691805T3 DK 1691805 T3 DK1691805 T3 DK 1691805T3 DK 04798326 T DK04798326 T DK 04798326T DK 04798326 T DK04798326 T DK 04798326T DK 1691805 T3 DK1691805 T3 DK 1691805T3
Authority
DK
Denmark
Prior art keywords
acid
cell cytoplasm
agent
urocanoic
converting cell
Prior art date
Application number
DK04798326T
Other languages
English (en)
Inventor
Lasse Leino
Jarmo Laihia
Original Assignee
Biocis Pharma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29763491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1691805(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocis Pharma Oy filed Critical Biocis Pharma Oy
Application granted granted Critical
Publication of DK1691805T3 publication Critical patent/DK1691805T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK04798326T 2003-12-09 2004-11-26 Anvendelse af urocansyre som er i stand til at omdanne celle cytoplasm til syre DK1691805T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20031793A FI20031793A0 (fi) 2003-12-09 2003-12-09 Uusi anti-proliferatiivinen farmaseuttinen koostumus
PCT/FI2004/000717 WO2005056007A1 (en) 2003-12-09 2004-11-26 The use of urocanic acid being able to acidify the cell cytoplasm and for preventing or halting cellular proliferation in a person

Publications (1)

Publication Number Publication Date
DK1691805T3 true DK1691805T3 (da) 2008-10-06

Family

ID=29763491

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04798326T DK1691805T3 (da) 2003-12-09 2004-11-26 Anvendelse af urocansyre som er i stand til at omdanne celle cytoplasm til syre

Country Status (17)

Country Link
US (2) US20060189691A1 (da)
EP (1) EP1691805B1 (da)
JP (1) JP4825680B2 (da)
CN (1) CN1889950B (da)
AT (1) ATE396723T1 (da)
AU (1) AU2004296570B2 (da)
CA (1) CA2544720C (da)
CY (1) CY1108163T1 (da)
DE (1) DE602004014187D1 (da)
DK (1) DK1691805T3 (da)
ES (1) ES2303113T3 (da)
FI (1) FI20031793A0 (da)
PL (1) PL1691805T3 (da)
PT (1) PT1691805E (da)
SI (1) SI1691805T1 (da)
WO (1) WO2005056007A1 (da)
ZA (1) ZA200602940B (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20030379A0 (fi) * 2003-03-14 2003-03-14 Lasse Leino Uusi farmaseuttinen koostumus

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE126058T1 (de) * 1990-06-29 1995-08-15 Bode Chemie Gmbh & Co Dermatologische zusammensetzungen mit einem gehalt an cis-urocaninsäure.
US5455036A (en) * 1990-06-29 1995-10-03 Bode Chemie Method of using cis-urocaninic acid for topically treating psoriasis
DE4122497C2 (de) 1991-07-02 1998-03-26 Wogepharm Gmbh Verwendung von trans-Urokaninsäure bei der prophylaktischen Therapie der Psoriasis
CA2114968A1 (en) * 1993-02-25 1994-08-26 John Wille Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
US5843979A (en) * 1993-02-25 1998-12-01 Bristol-Myers Squibb Company Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
GB9306473D0 (en) * 1993-03-29 1993-05-19 Bioglan Lab Ltd Pharmaceutically useful compounds
US5686100A (en) * 1994-11-22 1997-11-11 E.R. Squibb & Sons, Inc. Prophylactic and therapeutic treatment of skin sensitization and irritation
US5576013A (en) * 1995-03-21 1996-11-19 Eastern Virginia Medical School Treating vascular and neoplastic tissues
WO1997047355A1 (en) * 1996-06-12 1997-12-18 Alza Corporation Reduction of skin sensitization in electrotransport drug delivery
DE19638064C2 (de) * 1996-09-18 1998-08-20 Voith Turbo Kg Verfahren zur Steuerung von Schaltvorgängen bei einem Fahrzeuggetriebe
DE19817295A1 (de) * 1998-04-18 1999-10-21 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an unsymmetrisch substituiertenTriazinderivaten zum Erhalt des Urocaninsäurestatus der Haut
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
CA2406390A1 (en) * 2000-04-14 2001-10-25 University Of South Carolina Research Foundation Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
US6582734B1 (en) 2000-07-20 2003-06-24 Ecolab Inc. Antimicrobial composition useful for the treatment of bovine mastitis
US6541509B2 (en) * 2000-09-15 2003-04-01 Albert Einstein College Of Medicine Of Yeshiva University Method for treating neoplasia using combination chemotherapy
FI20030379A0 (fi) * 2003-03-14 2003-03-14 Lasse Leino Uusi farmaseuttinen koostumus

Also Published As

Publication number Publication date
CA2544720A1 (en) 2005-06-23
AU2004296570B2 (en) 2011-01-06
JP4825680B2 (ja) 2011-11-30
WO2005056007A1 (en) 2005-06-23
JP2007513927A (ja) 2007-05-31
US8338475B2 (en) 2012-12-25
SI1691805T1 (sl) 2008-08-31
CN1889950B (zh) 2011-02-09
ATE396723T1 (de) 2008-06-15
CN1889950A (zh) 2007-01-03
AU2004296570A1 (en) 2005-06-23
ZA200602940B (en) 2007-07-25
PT1691805E (pt) 2008-06-12
CY1108163T1 (el) 2014-02-12
PL1691805T3 (pl) 2008-11-28
DE602004014187D1 (de) 2008-07-10
EP1691805A1 (en) 2006-08-23
CA2544720C (en) 2012-01-03
EP1691805B1 (en) 2008-05-28
ES2303113T3 (es) 2008-08-01
FI20031793A0 (fi) 2003-12-09
US20060189691A1 (en) 2006-08-24
US20060189692A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
NO20051854L (no) Vedvarende frigivelse opioidformuleringer og fremgangsmater for anvendelse.
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
NO20064670L (no) Galeniske formuleringer av organiske forbindelser
SE9900961D0 (sv) Novel compounds
MY144659A (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
SE0401342D0 (sv) Therapeutic compounds
EA200400689A1 (ru) Фармацевтические и косметические композиции, содержащие ароматические альдегиды, содержащие оксигруппу
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
SE9802208D0 (sv) Novel compounds
SE0102440D0 (sv) New compound
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
TW200603787A (en) Topical preparations containing ambroxol
SE0401655D0 (sv) New compounds
DK1150704T3 (da) Melagatran til behandling af betændelse
ATE359066T1 (de) Pflaster mit 4-biphenylessigsäure
SE9802209D0 (sv) Novel compounds
BR0011880A (pt) Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica
CY1107346T1 (el) Φαρμακευτικη συνθεση για την ενδοκυτταρια οξινιση με cis-ουροκανικο οξυ
FI20031793A0 (fi) Uusi anti-proliferatiivinen farmaseuttinen koostumus
ECSP045210A (es) 2' - halo - 3' , 5' - dialcoxi - fen - 1' - il - imino - 2 -imidazolidinas y su uso como un fármaco
SE0402763D0 (sv) Nitro indazole derivatives